Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

29 Oct 2020 07:00

RNS Number : 5345D
Biome Technologies PLC
29 October 2020
 

29 October 2020

Biome Technologies plc

("Biome", the "Group" or the "Company")

Trading Update

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today provides a trading update for the nine months ended 30 September 2020.

 

Bioplastics Division

 

Revenues in the Bioplastics division in Q3 at £1.6m were 48% ahead of the previous quarter (Q2 2020: £1.1m) and 131% ahead of the prior year comparative (Q3 2019: £0.7m).

 

The division's revenues in the first nine months of the financial year stood at £3.8m, 93% ahead of the equivalent period last year (2019: £2.0m).

 

Revenues in Q3 reflected strong underlying demand for products that have been commercialised for some time (e.g. outer packaging and non-woven filter mesh applications for the US coffee market), coupled with growing revenues in rigid materials used in coffee pods. The Board expects revenues in Q4 to be below the Q3 quarterly level but in line with its expectations for this financial year.

 

The Bioplastics division is working with an expanding list of potential new customers, particularly in the US. Developmental work related to this continues with some vigour, despite the impact of Covid-19. In particular, the implementation of a filtration mesh project with a second US end-customer has moved forward assuredly and initial revenues are expected later this quarter.

 

During Q3, the activities of the Bioplastics division were recognised when Biome received the London Stock Exchange's Green Economy Mark. The Green Economy Mark, launched in 2019, recognises listed companies and funds which derive 50% or more of their revenues from environmental solutions.

 

Stanelco RF Technologies Division

 

Revenues in the RF Technologies division in Q3 were £0.2m (Q3 2019: £0.6m), resulting in revenues in the first nine months of the financial year of £0.6m (2019: £2.8m).

 

The fibre optic cable market, normally a major driver of the business, remains impacted by both over-capacity and COVID-19 disruption. The division continues to make a concerted effort to increase its geographic footprint and range of applications and already benefits from recurring revenue from power generation, medical and general industrial markets.

The business has continued to win small projects in the UK induction heating and welding market, but overall demand remains subdued.

 

 

Group Performance

 

Total Group revenues in Q3 were £1.8m (2019: £1.3m) taking Group revenues for the nine months to 30 September 2020 to £4.3m (2019: £4.7m). It is to be noted that all revenue figures in this statement exclude grant income (£38,000 in the third quarter of this year and £124,000 for the nine months).

 

Costs and capital expenditure continue to be managed tightly and as the Government furlough scheme ends in October, activity levels are such that staff are returning to normal duties.

 

The Group's cash position as at 30 September 2020 was £0.9m (30 June 2020: £1.1m) and the Group had no debt.

 

 

In September 2020, the Group announced that it had raised £1.1m (£1.0m net of costs), via a fundraising made up of three tranches, to support and accelerate the Bioplastics division's growth. Shareholder approval was obtained on 12 October 2020 and the net proceeds from the first and second tranches have now been received which enhances the Group's cash position from that at the end of Q3.

 

Group Outlook

 

The funds from the recent fundraise will support a vigorous approach to growing the Group's bioplastics business. It is against the above that the Board expects the full year results to be in line with current market expectations.

 

Ends-

 

For further information please contact: Biome Technologies plc

Paul Mines, Chief Executive Officer

Donna Simpson-Strange, Company Secretary

info@biometechnologiesplc.co.uk

Tel: +44 (0) 2380 867 100

www.biometechnologiesplc.com

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner (Equity Sales)

Tel: +44 (0) 20 3328 5656

www.allenbycapital.com

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where value-added pricing can be justified and which are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited.

Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers.

Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

 

www.biometechnologiesplc.com

www.biomebioplastics.com and www.thinkbioplastic.com 

www.stanelcorftechnologies.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTKKFBNCBDDKKB
Date   Source Headline
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular
1st Aug 20057:01 amRNSDirector Appointment
28th Jul 20057:01 amRNSUpdate re: trials with ASDA
26th Jul 20057:00 amRNSContract Win
19th Jul 20057:00 amRNSRe Agreement
5th Jul 20057:01 amRNSRe Joint Venture
29th Jun 20057:00 amRNSInterim Results
22nd Jun 20057:00 amRNSUpdate re trials with Asda
8th Jun 20055:29 pmRNSAdditional Listing
8th Jun 200510:00 amRNSAppointment of Group MD
8th Jun 20057:50 amRNSPlacing of Ordinary Shares
6th Jun 20057:01 amRNSAcquisition
3rd Jun 20053:02 pmRNSIssue of Equity
23rd May 20057:01 amRNSRe Contract
17th May 200512:12 pmRNSAdditional Listing
10th May 20057:00 amRNSUpdate re. trials with Asda
29th Apr 20053:46 pmRNSHolding(s) in Company
25th Apr 20053:27 pmRNSDirector Shareholding
22nd Apr 20052:24 pmRNSResult of AGM
22nd Apr 200511:31 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.